Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of ...

Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical ...

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...

Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.

Operator: Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...